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PRESCRIPTION DRUG SYSTEMS AND 
PRICE CONTROL IN CANADA 
Robert S. Nakagawa∗
INTRODUCTION 
This Article presents a brief overview of the regulation of 
prescription drugs in Canada. Part I provides an overview and 
the context of the environment in which the system operates; 
Part II describes the responsibilities of the federal government; 
Part III reviews the national initiatives that have been undertaken 
cooperatively between the federal and provincial/territorial 
governments; and Part IV describes the responsibilities of the 
provincial governments. 
I.  OVERVIEW AND CONTEXT 
With a relatively small population of 33.1 million people 
inhabiting 9,984,670 square kilometers (nearly 4 million square 
miles), Canada is the world’s 38th most populous country1 and 
the second largest.2 It is a constitutional monarchy with two 
 
∗ B.Sc. (Pharm.), FCSHP, ACPR. Assistant Deputy Minister, Ministry 
of Health, British Columbia, Canada; Adjunct Professor, Faculty of 
Pharmaceutical Sciences, University of British Columbia. 
1 Central Intelligence Agency, The World Factbook, 
https://www.cia.gov/cia/publications/factbook/rankorder/2119rank.html (last 
visited Apr. 12, 2007). 
2 Central Intelligence Agency, The World Factbook, https://cia.gov/cia/ 
publications/factbook/geos/ca.html (last visited Apr. 12, 2007). 
3 Gregory P. Marchildon, Health Systems in Transition: Canada, WHO 
Regional Office for Europe on behalf of the European Observatory on Health 
Systems and Policies 8 (2005), available at http://www.euro.who.int/ 
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constitutionally recognized orders of government: the federal 
government, and the provinces and territories.3 The country is 
divided into 10 provinces and three territories. With an average 
life span of 79.9 years, Canadians live slightly longer than 
Americans, whose average life span is 77.5 years, and spend 
significantly less on health care (9.9 percent versus 15.3 percent 
of GDP). 
Canadians place a high degree of importance on health care. 
The Commission on the Future of Health Care in Canada (the 
Romanow Commission) identified Medicare as “a defining 
aspect of our citizenship and an expression of social cohesion.”4 
Public sources fund 70 percent of the costs of the health care 
system in Canada, while the remaining 30 percent comes from 
the private sector.5
Drug therapy is the cornerstone of modern medical care in 
Canada. The number of drugs available to treat, diagnose and 
prevent disease has increased steadily over the last 30 years. As 
the number of available drugs has increased, so has their use. 
The Romanow report found that 300 million prescriptions, an 
average of 10 per person, are filled in Canada annually.6 Drug 
expenditures have followed suit. In 1985, the total expenditure 
on drugs in Canada was $3.8 billion; this figure was forecast to 
hit $24.8 billion by 2005.7
 
Document/E87954.pdf. 
4 Roy J. Romanow, Q.C., Building on Values: The Future of Health 
Care in Canada xxi (2002), available at http://www.hcsc.gc.ca/ 
english/pdf/romanow/pdfs/HCC_Final_Report.pdf. 
5 Exploring the 70/30 Split: How Canada’s Health Care System is 
Financed. Canadian Institute for Health Information, Ottawa, Ontario 3 
(2005), available at http://secure.cihi.ca/cihiweb/products/FundRep_EN.pdf. 
6 Romanow, supra note 4 at 191. 
7 Drug Expenditures in Canada 1985 to 2004. Canadian Institute for 
Health Information, Ottawa, Ontario 11 (2005), available at http://dsp-
psd.pwgsc.gc.ca/Collection/H115-27-2004E.pdf. 
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A.  Who Does What? 
Federal, provincial, and national structures and programs are 
primarily responsible for health care in Canada. National 
initiatives involve the cooperation of the federal, provincial, and 
territorial governments. The breakdown of federal, national and 
provincial responsibilities for prescription drugs is as follows: 
Federal 
• Approval of new drugs for sale 
• Patent drug pricing 
National (includes Federal, Provincial and Territorial 
 Participants) 
• Evidence-based drug reviews (through the Common 
Drug Review) 
• Formulary recommendations (through the Canadian 
Expert Drug Advisory Committee) 
Provincial 
• Drug plan formulary decisions 
• PharmaNet Systems 
II.  FEDERAL GOVERNMENT RESPONSIBILITIES 
The federal government’s role in the health system involves: 
(1) Setting and administering national principles and 
standards for the health care system. For example, the 
Canada Health Act requires that medical and hospital 
services are provided free of charge to Canadians. The 
five principles of the Canada Health Act are public 
administration, comprehensiveness, universality, 
portability and accessibility. Provinces must meet these 
criteria in the delivery of health care services in order to 
receive full federal contributions.8 
(2) Assisting in the financing of provincial health care 
 
8 CANADA HEALTH ACT OVERVIEW (November 25, 2002), 
http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/2002/2002_care-soinsbk4_e.html 
(last visited January 14, 2007). 
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services through fiscal transfers (there were $32.5 
billion in cash and tax transfers during 2006-2007).9 
(3) Delivering direct health services to specific groups 
including veterans, native Canadians, persons living on 
reserves, military personnel, inmates of federal 
penitentiaries and the RCMP. Their drug plans cover 
1.2 million Canadians. 
(4) Health protection, disease prevention and health 
promotion. 
(5) Regulating the safety, efficacy and quality of drugs. The 
Therapeutic Products Directorate is responsible for 
ensuring that prescription drugs marketed in Canada are 
safe and effective. The Directorate is committed to 
ensuring that decisions made are evidence-based and 
timely.10 
(6) The price of patented medicines (through the Patented 
Medicines Prices Review Board). 
While not its primary role, the federal government is 
responsible for the delivery of health care services provided to 
the military, First Nations, corrections, and veterans groups. 
A.  Federal Price Controls11
Price control of patented medicines is the responsibility of 
the Patented Medicines Prices Review Board (PMPRB). The 
PMPRB is an independent body created by Parliament in 1987 
under the Patent Act. It was established at the same time that 
patent protection was extended for pharmaceuticals as a safety 
net to ensure that Canadians were not paying an excessive price 
 
9 GOVERNMENT OF CANADA: DEPARTMENT OF FINANCE, CANADA 
HEALTH TRANSFER (FEDERAL TRANSFERS TO PROVINCES AND TERRITORIES, 
May 2006), http://www.fin.gc.ca/FEDPROV/chte.html (last visited Jan. 13, 
2007). 
10 GOVERNMENT OF CANADA: HEALTH, DRUGS AND HEALTH, 
http://www.hc-sc.gc.ca/dhp-mps/index_e.html (last visited Jan. 14, 2007). 
11 GOVERNMENT OF CANADA: PATENT MEDICINE PRICES REVIEW BOARD, 
WELCOME!, http://www.pmprb-cepmb.gc.ca/english/home.asp?x=1 (last 
visited Jan. 13, 2007). 
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at the same time that manufacturers enjoyed a longer duration of 
market exclusivity. The PMPRB is a quasi-judicial tribunal that 
sets price guidelines and has the power to roll back prices that 
are deemed excessive. Figure 1 shows the amount of 
prescription drug sales in Canada from 1993 to 2005. 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 2.4 2.6 3.0
3.7 4.3
5.4 6.3
7.5
8.8
10.1 10.9
11.5
2.6 2.9 2.8
2.9
2.6
2.7
2.7
2.8
2.9
2.9
3.3
3.0 2.5
0.4 0.6
0.6
0.7 0.7
0.8
0.8
0.9
1.0
1.4
1.7
2.0 2.1
5.4
5.9 6.0
6.6 7.0
7.8
8.9
10.0
11.5
13.1
15.0
16.115.9
0
2
4
6
8
10
12
14
16
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Source: PMPRB and IMS Health
$ 
B
ill
io
ns
Generic
Non-Patented Brand Name
Patented
  
 
It should be noted that the PMPRB only has jurisdiction over 
patented prescription drugs, and as such does not have the 
authority to regulate non-patented drugs including generic drugs, 
prices charged by wholesalers or retailers, or pharmacists’ 
professional fees. Rather, the PMPRB determines whether a 
price set by a manufacturer is excessive by employing the 
following guidelines: 
• Existing patented drug prices cannot increase by more 
than the Consumer Price Index; 
• New patented drug prices are limited so that the cost 
of therapy is in the range of the cost of therapy for 
existing drugs used to treat the same disease; and 
• Breakthrough drug prices are limited to the median of 
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the prices for the same drugs charged in other 
specified industrialized countries that are set out in 
the Regulations under the Patent Act (France, 
Germany, Italy, Sweden, Switzerland, the U.K. and 
the U.S.). The determination of “breakthrough” is 
made by an expert advisory committee established by 
the PMPRB. 
The impact of the PMPRB on patented drug prices in 
Canada relative to the defined comparator countries is shown in 
Figure 2. The ratio indicated along the y-axis represents the 
ratio of foreign prices to Canadian prices for patented drugs in 
the years 1987, 1997 and 2005. The relative price of 
prescription drugs in Canada has been reduced from 73 percent 
to 58 percent of the U.S. price. It is clear that the U.S. pays the 
highest price for prescription drugs among the comparator 
countries. 
Figure 2 
 
 
 
 
 
 
 
 
 
13
6
80
89
10
6
10
0 11
1
10
1
12
4
15
6
84
93 9
7 10
0 10
7
10
6 11
6
17
2
93
70
84
10
0
73
5350
 
0
20
40
60
80
100
120
140
160
180
200
Italy France Sweden Canada Germany UK Switzerland US
R
at
io
 
 
Increases in health spending relative to increases in other 
publicly funded services in Canada are a growing concern. In 
British Columbia, the Ministry of Health spent almost 42 
percent of the provincial budget in the fiscal year of 2004-2005 
on health care.12 Average annual increases in expenditures have 
 
 
12 PROVINCE OF BRITISH COLUMBIA: MINISTRY OF HEALTH, 
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been approximately 8 percent per year, while Provincial 
revenues are anticipated to grow by approximately 3 percent per 
year. This 5 percent difference between revenues and 
expenditures is a significant concern to the government of 
British Columbia. At that rate, health expenses have the 
potential to consume all provincial expenditures other than 
education by the fiscal year 2018.13
Prescription drug expenses in British Columbia are 
increasing at an even greater rate. Over the last five years, the 
average increase in spending has been approximately 9 percent 
per year. This could be considered a worthwhile investment in 
health if the drugs funded generally represented significant 
advances in therapy, and resulted in better patient outcomes 
(reduced physician visits, hospitalizations and emergency 
department visits). However, this is not the case. While some 
drugs are true therapeutic breakthroughs, most of them are not. 
Prescrire,14 a French publication, is one of the few publications 
that places a value on new medicines, rating them on a scale 
ranging from “not acceptable” to “bravo.” Figure 3 shows that 
over the period 1981 to 2005, of 3,122 reviewed drugs or 
indications, more than two-thirds of them were “nothing new.” 
Only 2 percent were considered to be real advances, and a mere 
seven drugs (0.22 percent) were considered to be worthy of a 
“bravo” rating.15
 
CONVERSATION ON HEALTH, http://www.bcconversationonhealth.ca/428/368/ 
(last visited Jan. 13, 2007). 
13 PROVINCE OF BRITISH COLUMBIA: MINISTRY OF FINANCE, ECONOMIC 
AND FISCAL UPDATE (Sept. 15, 2006), http://www.fin.gov.bc.ca/qrt-
rpt/qr06/q1powerpoint.pdf (last visited Jan. 11, 2007). 
14 PRESCRIRE INTERNATIONAL, available at http://www.prescrire.org/ 
signature/productions/international.php. 
15 A review of new drugs in 2004: Floundering innovation and increased 
risk-taking, PRESCRIRE INTERNATIONAL, April 2005, vol.14, n. 76 pp. 68-73. 
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Figure 3 
New Products Ratings 1981–2005 
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Based on La Revue Prescrire with 3,122 drugs or new indications; does 
not include over-the-counter medications or product line extensions 
Prescrire Rating Scale: 
Bravo—The drug is a major therapeutic innovation in an area where 
previously no treatment was available. 
A Real Advantage—The product is an important therapeutic innovation 
but has certain limitations. 
Offers an Advantage—The product has some value but does not 
fundamentally change the present therapeutic practice. 
Possibly Helpful—The product has minimal additional value, and should 
not change prescribing habits except in rare circumstances. 
Judgment Reserved—The editors postpone their judgment until better 
data and a more thorough evaluation of the drug are available. 
Nothing New—The product may be a new molecule but is superfluous 
because it does not add to the clinical possibilities offered by previous 
products available. In most cases it concerns a me-too product. 
Not Acceptable—Product without evident benefit but with potential or 
real disadvantages. 
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III.  NATIONAL INITIATIVES 
The following sections describe the national initiatives, 
including the National Pharmaceuticals Strategy and the pooling 
of resources for drug plan reviews through the Common Drug 
Review and the Canadian Expert Drug Advisory Committee. 
A.  The National Pharmaceuticals Strategy17
First Ministers (the Prime Minister of Canada and the 
Premiers of each of the provinces and territories) agreed to 
implement a 10-year plan to strengthen health care in Canada. 
The National Pharmaceuticals Strategy is an important part of 
this plan. The following nine elements are involved in this 
strategy: 
• Develop, assess and cost options for catastrophic 
pharmaceutical coverage; 
• Establish a common National Drug Formulary for 
participating jurisdictions based on safety and cost 
effectiveness; 
• Accelerate access to breakthrough drugs for unmet health 
needs through improvements to the drug approval process; 
• Strengthen evaluation of real-world drug safety and 
effectiveness; 
• Pursue purchasing strategies to obtain best prices for 
Canadians for drugs and vaccines; 
• Enhance action to influence the prescribing behaviour [sic] 
of health care professionals so that drugs are used only 
when needed and the right drug is used for the right 
problem; 
• Broaden the practice of e-prescribing through accelerated 
development and deployment of the Electronic Health 
Record; 
• Accelerate access to non-patented drugs and achieve 
 
17 FEDERAL/PROVINCIAL/TERRITORIAL MINISTERIAL TASK FORCE, 
NATIONAL PHARMACEUTICALS STRATEGY PROGRESS REPORT 4 (2006), 
available at http://www.hc-sc.gc.ca/index_e.html. 
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international parity on prices of non-patented drugs; and 
• Enhance analysis of cost drivers and cost-effectiveness, 
including best practices in drug plan policies. 
In September 2006, a progress report was released.18 The 
report outlined the current status and progress of each of the 
NPS elements as well as highlighting the priority work for the 
next year. In addition, there was a commitment by the 
governments to involve stakeholders to a greater degree in the 
development of initiatives. 
B.  Drug Plan Formulary Decisions 
There are 19 publicly funded drug plans in Canada: one for 
each of the 10 provinces and three territories, as well as six 
federal plans. Beneficiaries under each of these plans are 
determined by the jurisdiction. While most of the plans provide 
coverage for seniors and low-income families, some are more 
universally available with varying degrees of deductibles and co-
pays. Until 2002 each plan undertook its own review of the 
drug’s therapeutic and economic profile.19
C.  The Common Drug Review20
In 2002, a Common Drug Review (CDR) process was 
established to provide a single drug review to serve as the basis 
for drug formulary decisions in each of the drug plans. 
Manufacturers of public drug plans submit requests for drugs to 
be reviewed by the CDR for new drugs that have been approved 
for sale in Canada by Health Canada, and have not previously 
been available.21 The staff prepares a common drug review 
 
18 Id. 
19 Health Canada, Common Drug Review, http://www.hc-sc.gc.ca/hcs-
sss/pharma/mgmt-gest/cdr-emuc/index_e.html (last visited Mar. 22, 2007). 
20 Canadian Agency for Drugs and Technology in Health, Canadian 
Expert Drug Advisory Committee. http://www.cadth.ca/index.php/en/ 
cdr/committees/cedac (last visited Mar. 22, 2007). 
21 The submission requirements are available at http://www.cadth.ca/ 
media/cdr/process/CDR_SubmissionGuidelines_2006_ Sept20.pdf. 
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document based on the submission and independent literature 
searches. The drug manufacturer then comments on the review 
before it is finalized. 
D.  Canadian Expert Drug Advisory Committee22
The Canadian Expert Drug Advisory Committee (CEDAC) 
is an 11-member independent advisory body with expertise in 
drug therapy and drug evaluation, and has two new public 
members as of the fall of 2006. The CEDAC is responsible for 
reviewing the final CDR and developing formulary 
recommendations for consideration by each of the public drug 
plans. Listing recommendations are provided confidentially to 
the drug plans and the manufacturer under embargo to allow for 
comment. The final recommendations, along with the basis for 
said recommendations, are posted on the website. 
IV.  PROVINCIAL GOVERNMENT RESPONSIBILITIES 
In general, the provincial governments are responsible for 
managing and delivering health care services within their 
jurisdiction, which involves planning, financing, and evaluation 
and provision of hospital care, physician and allied health care 
services, as well as the regulation of the practices of the health 
professions. Although payment for prescription drugs is not 
required under the Canada Health Act, every province offers 
some form of drug insurance to their citizens. The beneficiary 
and drug coverage parameters vary widely among the plans. 
 
22 Government of British Columbia PharmaCare, PharmaNet, 
http://www.healthservices.gov.bc.ca/pharme/pharmanet/netindex.html (last 
visited Mar. 22, 2007). 
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A.  Drug Plan Decisions 
Each of the drug plans make listing and coverage decisions 
based on: 
• CEDAC’s recommendation 
• Their mandates, priorities and resources 
• Generic price limits and drug substitution 
requirements 
• The availability of therapeutic reference-based pricing 
• The availability of policies that ensure that more 
expensive drugs are only provided when pre-
determined criteria (Special Authorization, Prior 
Authorization) are met 
B.  PharmaNet—Provincial Pharmacy Network23
British Columbia has one of the most comprehensive 
pharmaceutical databases in the world. Since 1995, pharmacists 
have been required by law to enter all community prescriptions 
into the database. This legislation was targeted at ensuring better 
patient safety by reducing preventable adverse events and 
hospital admissions by the early identification of drug 
interactions, allergies and other therapeutic problems by the 
pharmacist. It was felt that a pharmacist would not be able to 
safely dispense a prescription drug without access to a complete 
drug profile for the patient. The current drug database now 
includes all prescriptions dispensed in British Columbia 
pharmacies since 1995. 
In addition to these clinical benefits, the PharmaNet system 
allows pharmacists to monitor for prescription drug abusers and 
prevent prescription fraud. Work is currently underway to 
establish a pan-Canadian standard for drug information systems 
to support the development of PharmaNet systems throughout 
 
23 Canada Health Infoway, Drug Information Systems, 
http://www.infoway-inforoute.ca/en/WhatWeDo/DrugsInfo.aspx (last visited 
Mar. 22, 2007). 
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Canada. This is being developed with support from Canada 
Health Infoway and supported by both the federal, provincial 
and territorial governments.24
CONCLUSION 
Health care in Canada is provided largely through support 
from the federal, provincial and territorial governments. The 
federal government is responsible for the approval of new drugs 
for sale in Canada as well as the regulation of patent drug 
pricing. Provincial governments are responsible for their own 
drug plan design and for determination of the drugs for which 
they will provide payment. They also operate independent 
prescription drug systems, such as PharmaNet, to ensure the 
safe and efficient dispensing of prescription drugs. 
There are many aspects of the Canadian health care system 
that may be of interest to U.S. policy makers. Drug price 
regulation for patented medicines could provide more accessible 
prescription drugs in the U.S. Cooperation between the federal 
and provincial/territorial governments to advance the national 
pharmaceutical agenda and share rigorous reviews of new drugs 
has been valuable in Canada. Similar cooperation in the U.S. 
may provide similar benefits. Finally, government sponsored, 
comprehensive electronic prescription databases may provide an 
additional element of safety for patients, protecting them from 
untoward drug effects resulting from drug interactions or other 
sensitivities. 
 
 
24 Id. 
